AQST Aquestive Therapeutics Inc

Price (delayed)

$3.58

Market cap

$131M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.58

Enterprise value

$197.27M

Highlights
The EPS has grown by 37% year-on-year and by 4.8% since the previous quarter
Aquestive Therapeutics's gross margin has increased by 30% YoY and by 4.6% QoQ
Aquestive Therapeutics's quick ratio has decreased by 36% YoY but it has increased by 2.2% QoQ
AQST's equity has dropped by 149% year-on-year and by 7% since the previous quarter
The debt has grown by 44% YoY and by 4.8% from the previous quarter

Key stats

What are the main financial stats of AQST
Market
Shares outstanding
36.59M
Market cap
$131M
Enterprise value
$197.27M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.09
Earnings
Revenue
$48.21M
EBIT
-$37.58M
EBITDA
-$34.27M
Free cash flow
-$46.41M
Per share
EPS
-$1.58
Free cash flow per share
-$1.3
Book value per share
-$1.43
Revenue per share
$1.36
TBVPS
$1.74
Balance sheet
Total assets
$61.92M
Total liabilities
$113.72M
Debt
$93.77M
Equity
-$51.8M
Working capital
$24.39M
Liquidity
Debt to equity
-1.81
Current ratio
2.22
Quick ratio
1.88
Net debt/EBITDA
-1.93
Margins
EBITDA margin
-71.1%
Gross margin
75%
Net margin
-111.9%
Operating margin
-77.9%
Efficiency
Return on assets
-90.3%
Return on equity
N/A
Return on invested capital
-41.5%
Return on capital employed
-89.7%
Return on sales
-78%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AQST stock price

How has the Aquestive Therapeutics stock price performed over time
Intraday
-4.79%
1 week
7.83%
1 month
-19.37%
1 year
-30.21%
YTD
-33.08%
QTD
-9.82%

Financial performance

How have Aquestive Therapeutics's revenue and profit performed over time
Revenue
$48.21M
Gross profit
$36.14M
Operating income
-$37.56M
Net income
-$53.93M
Gross margin
75%
Net margin
-111.9%
Aquestive Therapeutics's gross margin has increased by 30% YoY and by 4.6% QoQ
The operating income has increased by 30% YoY and by 12% from the previous quarter
Aquestive Therapeutics's operating margin has increased by 29% YoY and by 17% QoQ
The company's gross profit rose by 28% YoY and by 10% QoQ

Growth

What is Aquestive Therapeutics's growth rate over time

Valuation

What is Aquestive Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.09
The EPS has grown by 37% year-on-year and by 4.8% since the previous quarter
AQST's equity has dropped by 149% year-on-year and by 7% since the previous quarter
AQST's P/S is 22% below its last 4 quarters average of 3.4
Aquestive Therapeutics's revenue has increased by 5% from the previous quarter

Efficiency

How efficient is Aquestive Therapeutics business performance
The company's return on invested capital has surged by 52% YoY and by 19% QoQ
The return on sales has grown by 34% year-on-year and by 16% since the previous quarter
AQST's ROA is up by 20% year-on-year and by 2.4% since the previous quarter

Dividends

What is AQST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AQST.

Financial health

How did Aquestive Therapeutics financials performed over time
The company's total assets is 46% lower than its total liabilities
Aquestive Therapeutics's quick ratio has decreased by 36% YoY but it has increased by 2.2% QoQ
Aquestive Therapeutics's total liabilities has increased by 33% YoY and by 2.1% QoQ
AQST's equity has dropped by 149% year-on-year and by 7% since the previous quarter
The debt has grown by 44% YoY and by 4.8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.